OR WAIT null SECS
Markus Magerl, MD, from Charité-Universitätsmedizin Berlin.
March 10, 2026
Video
At AAAAI 2026, Magerl discusses phase 2 data showing BW-20805 reduced hereditary angioedema attacks by up to 100% with dosing intervals of up to 6 months.